U.S. Paper and Forestry Products Stock News

Roper Technologies (ROP) is back on investors’ radar after a Q1 earnings beat, a fresh US$1.5b share buyback authorization, and a reaffirmed US$0.91 quarterly dividend, alongside shareholder support for its existing business structure. See our latest analysis for Roper Technologies. Despite the Q1 earnings beat, new US$1.5b buyback, and a reaffirmed dividend, the stock has been under pressure. The share price is down 24.76% year to date and the 1 year total shareholder return has declined...

Earlier this week, Airbnb announced it is expanding beyond home rentals by adding services such as car rentals, airport pickups, grocery delivery, luggage storage, and more independent hotels, including exclusive offerings linked to the 2026 FIFA World Cup. This move signals Airbnb’s push to become a broader travel services platform, aiming to diversify revenue and reduce reliance on heavily regulated short‑term rental markets. Next, we’ll examine how Airbnb’s push into car rentals and other...

Oracle (ORCL) is back in focus for investors after recent share price moves, with the stock now around $192 and a market value of about $552.4b. This has prompted fresh attention on its valuation. See our latest analysis for Oracle. Recent trading tells a story of strong momentum building in Oracle’s share price, with a 10.85% 1 month share price return, a 35.93% 3 month share price return, and a 5 year total shareholder return of 161.01%. If Oracle’s recent move has you rethinking your tech...

Twist Bioscience (TWST) recently launched its Complex Genes offering, which supports DNA sequences up to 7,000 base pairs and accepts designs that were previously difficult to manufacture at scale for drug discovery applications. See our latest analysis for Twist Bioscience. That Complex Genes launch comes on the back of strong recent momentum, with an 87% year to date share price return and a very large 3 year total shareholder return of 320.33%, although the 5 year total shareholder return...

In late March, Echodyne, Moog Inc., and partners conducted the Operation Condor Rebirth exercise at Fort Hood, Texas, showing that Moog’s modular weapons platform, paired with Echodyne’s EchoShield radar and AI targeting, can detect, track, and engage small drone threats in under three seconds. This live-fire validation of rapidly upgrading existing turreted weapon stations into effective counter‑UAS systems highlights Moog’s role in providing adaptable, AI-enabled defense solutions for...

Tanger Inc. recently released its 2025 Impact Report, marking ten years of sustainability reporting, and highlighted achievements such as a 12% rise in solar energy generation capacity and recognition as a 2026 Green Lease Leader at the Silver level. These milestones reinforce Tanger’s emphasis on environmental, social and governance practices, which can be material to how some investors assess long-term business quality and risk. We’ll now examine how Tanger’s enhanced sustainability...

Earlier this month, Rigetti Computing signed a past-dated letter of intent with the U.S. Department of Commerce for up to US$100 million over three years under the CHIPS Act, in exchange for an equity stake, to fund superconducting quantum computing research and development. This prospective government equity partnership effectively pairs Rigetti’s roadmap with federal quantum priorities, potentially reshaping how the company finances and organizes its long-horizon R&D projects. Next, we’ll...

MoonLake Immunotherapeutics recently reported a first-quarter 2026 net loss of US$69.71 million alongside a positive final pre-BLA meeting with the FDA aligning on submission plans and label strategy for sonelokimab in hidradenitis suppurativa. A key takeaway is the FDA’s confirmation that existing adult and adolescent trial data appear acceptable for a Biologics License Application, removing identified regulatory gaps and clarifying MoonLake’s US commercialization path for...

What triggered the latest move in Doximity (DOCS) Doximity (DOCS) recently issued financial results with revenue guidance that fell short of investor expectations, along with commentary on higher AI related expenses and margin pressures. This was followed by a securities law investigation from Pomerantz LLP. The combination of a softer forward outlook and concerns around the cost of AI investments has sharpened the market’s focus on how the company balances growth initiatives with...

Earlier in May 2026, Fifth Third Bancorp reported strong early participation in private exchange offers and consent solicitations for notes it assumed from Comerica, while also confirming that its CFO and chief credit officer had joined the 2026 Morgan Stanley US Financials Conference, with related materials briefly available on its investor relations site. Together, these actions highlight how management is reshaping the company’s funding profile while engaging institutional investors on...

Recent performance snapshot IPG Photonics (IPGP) has seen a mixed stretch recently, with the stock down 4.5% over the past month and 11.6% over the past 3 months, despite a 59.0% gain year to date. See our latest analysis for IPG Photonics. The share price has cooled recently, with a 7 day share price return of 15.8% but declines over the past month and quarter, while the 1 year total shareholder return of 84.21% highlights how strong earlier momentum has been. If IPG Photonics has you...

Energizer Holdings (ENR) continues to draw investor attention after a period of mixed share performance, with the stock up 5.1% over the past day but down 9.1% for the month and 19.9% over the past 3 months. See our latest analysis for Energizer Holdings. That short term momentum contrasts with a weaker backdrop, with the share price down over the year to date and the 1 year total shareholder return also in decline. This suggests recent buying interest may reflect shifting views on Energizer...

IQVIA Holdings stock performance snapshot IQVIA Holdings (IQV) has drawn investor attention after a mixed stretch for the stock, with a decline year to date but a gain over the past year and modest progress over the past month and past 3 months. See our latest analysis for IQVIA Holdings. At a share price of US$167.90, IQVIA’s recent moves show fading short term momentum, with the 1 day and 7 day share price returns slightly down, even as the 1 year total shareholder return remains strongly...

Recent commentary on Lincoln Electric Holdings, a profitable welding equipment maker, has highlighted below-benchmark organic revenue growth and shrinking returns on capital, pointing to mounting competitive pressures. What stands out is that earnings have only inched higher over the past two years, prompting questions about the company’s ability to sustain its historically strong profitability. Next, we’ll examine how concerns about Lincoln Electric’s slowing organic revenue growth may...

Why Stock Yards Bancorp Is On Investors’ Radar Today Stock Yards Bancorp (SYBT) has attracted fresh attention after recent share price moves, with the stock near US$71 and mixed return trends over the past year. This has prompted closer scrutiny from income and regional bank investors. See our latest analysis for Stock Yards Bancorp. Recent trading reflects steady interest, with the current US$71.22 share price coming after a 7-day share price return of 2.86% and a 90-day share price return...

Krystal Biotech (KRYS) is back in focus after the United Kingdom granted marketing authorization for VYJUVEK, the first genetic medicine approved there for dystrophic epidermolysis bullosa, with orphan status and potential 12-year exclusivity. See our latest analysis for Krystal Biotech. At a latest share price of US$299.45, Krystal Biotech has pulled back over the past week but still shows a 30 day share price return of 9.88% and a 1 year total shareholder return of 139.46% relating to...

Earlier in May 2026, the European Commission granted marketing authorization for Agios Pharmaceuticals’ PYRUKYND (mitapivat) to treat anemia in adults with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassemia, making it the only approved medicine across all EU member states for this broad thalassemia population. This decision not only broadens PYRUKYND’s labeled use beyond pyruvate kinase deficiency but also deepens Agios’ footprint in rare hematologic diseases...

Karooooo (KARO) stock is in focus after the company reported 20% revenue growth, strong gains in subscription and annual recurring revenue, a very large jump in free cash flow, and a 20% dividend increase. See our latest analysis for Karooooo. At a share price of $47.58, Karooooo has gained 2.30% over the last day and 5.57% over the past 90 days, but the 1-year total shareholder return is still down 7.58%. This comes after strong revenue growth, higher dividends, and new earnings guidance, so...

Zenas BioPharma recently reported that the first subject has been dosed in a Phase 1 trial of ZB021, an oral small‑molecule IL-17AA/AF inhibitor being tested in healthy volunteers in China in partnership with InnoCare Pharma. This program targets a space where no oral IL-17 inhibitors are currently approved or in late-stage development globally, potentially offering a differentiated option for autoimmune and inflammatory diseases. Next, we’ll examine how advancing ZB021 into Phase 1,...

In its latest quarterly report, ESCO Technologies posted revenues of US$309.3 million, an increase of 33.5% year on year, but below analyst expectations by 3.4%, with adjusted operating income also missing estimates. Management emphasized strong order growth and broad-based revenue strength across Navy, aerospace, Test, and utilities markets, underscoring resilient demand despite the softer-than-expected quarter. With ESCO delivering strong year-on-year growth yet missing analyst...

Granite Construction has recently completed a private offering of US$600,000,000 in 6.375% senior unsecured notes due 2034, guaranteed by certain domestic subsidiaries and sold under Rule 144A and Regulation S. The company plans to use the proceeds to retire its outstanding 3.75% Convertible Senior Notes due 2028, unwind related capped call structures, and potentially reduce revolving credit borrowings, reshaping its mix of fixed and convertible debt. We’ll now examine how replacing the...

Earlier this month, Artisan Partners Asset Management reported Q1 results that paired sizable equity outflows and near-term equity headwinds with ongoing growth in its credit and alternatives platforms, while outlining continued efforts in M&A, product development, and ETF capabilities. The earnings call emphasized how shifting asset mix and product innovation are becoming increasingly central to Artisan Partners’ effort to sustain earnings resilience despite pressure on traditional equity...

Ares Management (ARES) is in focus after partnering with The Scion Group in a joint venture to acquire a 12 property, 7,578 bed student housing portfolio for about US$910 million. See our latest analysis for Ares Management. The Ares Management share price has risen 8.6% over the past 90 days, including an 8.0% 30 day share price return, yet is still down 25.2% year to date, while the 5 year total shareholder return of 163.1% points to strong longer term performance momentum. If deals like...

Elevance Health (ELV) is back in focus after first quarter 2026 results showed adjusted EPS of $12.58, a 5.1% year-over-year increase, and management raised full year adjusted EPS guidance. See our latest analysis for Elevance Health. The first quarter numbers and guidance upgrade have coincided with stronger momentum in the stock, with a 14.5% 1 month share price return and 17.5% 3 month share price return, while the 3 year total shareholder return is still lower. If Elevance Health’s move...